Scientists define molecular on-off switches for cancer and autoimmunity

Sep 30, 2010

A new report published in the October 2010 print issue of The FASEB Journal offers a ray of hope in the search for new cancer drugs. By examining the seemingly conflicting roles of how oncogenes and tumor suppressor genes handle cellular stress, scientists from the Institute for Advanced Studies in New Jersey argue that each of these opposing systems could be potent drug targets in the effort to stop cancer. In addition, their hypothesis provides new insights into what contributes to immunological disorders such as chronic inflammation and autoimmune diseases.

"We hope the ideas put forward in this article will stimulate additional experiments to test these novel concepts," said Arnold Levine, Ph.D., co-author of the study from the Institute for Advanced Study in Princeton, New Jersey. "Among those experiments are the synthesis of new drugs to inhibit pathways that could change the course of a disease."

After a review of existing experimental literature, Levine and colleagues concluded that a new class of drugs could be developed to address the conflicting nature of oncogenes and . Specifically, the research paper published in The examines the roles of the and the oncogene, NF-kappaB. The p53 suppressor limits the consequences of stress by initiating cell death and promoting metabolic patterns in the cell. The oncogene NF-kappaB on the other hand, promotes cell division resulting in the synthesis of substrates for cell division.

These two cellular responses, both of which have evolved to handle different types of stress, have adopted opposite strategies and cannot function in the same cell at the same time. As a result, Levine and colleagues speculate that drugs could be developed to take advantage of the fact that if one factor is activated, the other is rendered inactive. This could be achieved at several places in both the p53 and NF-kappaB pathways where regulatory proteins act on both with opposite functional consequences.

"Our cells use the p53 and NF-kappaB pathways to respond to cellular stress: one controls cancer, the other immunity. If they get out of balance, we're in trouble.," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "Thanks to this work we can start restore the balance by means of new drugs."

Explore further: Body Mass Index associated with breast cancer, regardless of body shape

More information: Prashanth Ak and Arnold J. Levine. p53 and NF-kappaB: different strategies for responding to stress lead to a functional antagonism FASEB J. 2010 24: 3643-3652. DOI: 10.1096/fj.10-160549

add to favorites email to friend print save as pdf

Related Stories

Protein is linked to lung cancer development

Oct 22, 2009

(PhysOrg.com) -- A protein that normally helps defend cells from infection can play a critical role in the development of lung cancer, according to MIT cancer biologists.

Pathway links inflammation, angiogenesis and breast cancer

Aug 09, 2007

A well-known inflammatory protein spawns an enzyme that inactivates two tumor-suppressing genes, ultimately triggering production of new blood vessels to nourish breast cancer cells, researchers at The University of Texas ...

Recommended for you

Physicians target the genes of lung, colon cancers

3 hours ago

(Medical Xpress)—University of Florida physicians and researchers are collaborating to map the genes of different types of cancer, and then deliver medication to attack cancer at its source.

DNA alternative to Pap smear sparks medical debate (Update)

22 hours ago

A high-tech screening tool for cervical cancer is facing pushback from more than a dozen American patient groups, who warn that the genetic test could displace a simpler, cheaper and more established mainstay of women's health: ...

User comments : 0

More news stories

HIV+ women respond well to HPV vaccine

HIV-positive women respond well to a vaccine against the human papillomavirus (HPV), even when their immune system is struggling, according to newly published results of an international clinical trial. The study's findings ...